These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Changing approaches in the treatment of benign prostatic hyperplasia. Schröder FH Eur Urol; 1991; 20 Suppl 1():63-7. PubMed ID: 1722165 [TBL] [Abstract][Full Text] [Related]
9. Medical treatment of benign prostatic hyperplasia: 5 alpha-reductase inhibitors and alpha-adrenergic antagonists. Monda JM; Oesterling JE Mayo Clin Proc; 1993 Jul; 68(7):670-9. PubMed ID: 7688840 [TBL] [Abstract][Full Text] [Related]
10. [New conservative therapeutic approaches in benign prostatic hyperplasia]. Schulze H; Berges R; Paschold K; Senge T Urologe A; 1992 Jan; 31(1):8-13. PubMed ID: 1372777 [TBL] [Abstract][Full Text] [Related]
11. Medical management of prostatic diseases. Schlegel PN Adv Intern Med; 1994; 39():569-601. PubMed ID: 7511322 [TBL] [Abstract][Full Text] [Related]
12. Estrogen and androgen signaling in the pathogenesis of BPH. Ho CK; Habib FK Nat Rev Urol; 2011 Jan; 8(1):29-41. PubMed ID: 21228820 [TBL] [Abstract][Full Text] [Related]
13. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk. Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135 [TBL] [Abstract][Full Text] [Related]
15. The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia. Levine AC; Kirschenbaum A; Gabrilove JL Mt Sinai J Med; 1997 Jan; 64(1):20-5. PubMed ID: 8997072 [TBL] [Abstract][Full Text] [Related]
17. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists. Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746 [TBL] [Abstract][Full Text] [Related]
18. [Application of antiandrogens on prostatic diseases]. Takahashi S; Hasegawa F; Isurugi K Nihon Rinsho; 1994 Mar; 52(3):809-14. PubMed ID: 7513031 [TBL] [Abstract][Full Text] [Related]
19. Hormonal and morphologic evaluation of the effects of antiandrogens on the blood supply of the rat prostate. Shibata Y; Ono Y; Kashiwagi B; Suzuki K; Fukabori Y; Honma S; Yamanaka H Urology; 2003 Nov; 62(5):942-6. PubMed ID: 14624931 [TBL] [Abstract][Full Text] [Related]
20. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia. Habib FK; Ross M; Tate R; Chisholm GD Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]